DOCSLIB.ORG

Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019 Current Psychiatry Reports (2019) 21:124 https://doi.org/10.1007/s11920-019-1114-0 SCHIZOPHRENIA AND OTHER PSYCHIATRIC DISORDERS (AK PANDURANGI, SECTION EDITOR) Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016–March 2019 Luisa Peters 1 & Amanda Krogmann1 & Laura von Hardenberg 1 & Katja Bödeker1 & Viktor B. Nöhles1 & Christoph U. Correll1,2,3 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review This study was conducted in order to review randomized controlled trial (RCT) data published January 2016– March 2019 on long-acting injectable antipsychotics (LAIs) for schizophrenia. Recent Findings Thirty-one RCTs (primary studies = 7; post hoc analyses = 24; n = 4738) compared LAIs vs. placebo (studies = 11, n = 1875), LAIs vs. oral antipsychotics (OAPs) (studies = 7, n = 658), and LAI vs. LAI (studies = 13, n = 2205). LAIs included two new formulations, aripiprazole lauroxil nanocrystal dispersion and subcutaneously injectable risperidone Perseris, as well as aripiprazole lauroxil, aripiprazole once-monthly, paliperidone once-monthly, paliperidone 3-monthly, and risperidone- LAI. Regarding prevention of relapse and hospitalization, LAIs consistently outperformed placebo, being partly superior to OAPs, without relevant LAI–LAI differences. LAIs were comparable to OAPs regarding all-cause discontinuation, functioning, quality of life, and tolerability, being associated with higher patient satisfaction and service engagement. Recent meta-analyses yielded mixed results, but never favoring OAPs over LAIs. Summary In RCTs, LAIs are superior to placebo, but only in some aspects, superior to OAPs. Comparative effectiveness of LAIs vs. OAPs requires further study, ideally in generalizable/real-world samples. Keywords Schizophrenia . Antipsychotics . Long-acting injectables . Relapse . Hospitalization . Symptom improvement . Acceptability . Discontinuation . Meta-analyses Introduction comealongwaywiththeinitialdevelopment of antipsychotics and atypical antipsychotics [2–5], which have remained the only Schizophrenia remains one of the most severe medical diseases approved and effective pharmacologic treatment for schizophre- [1]. The treatment of this chronic and often disabling disorder has nia [4, 6•]. Despite pharmacologic advances in recent years, an Luisa Peters and Amanda Krogmann contributed equally to this work. This article is part of the Topical Collection on Schizophrenia and Other Psychiatric Disorders * Christoph U. Correll Viktor B. Nöhles [email protected] [email protected] Luisa Peters [email protected] 1 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Augustenburger Platz 1, Amanda Krogmann 13353 Berlin, Germany [email protected] 2 Laura von Hardenberg Psychiatry Research, The Zucker Hillside Hospital, Northwell [email protected] Health, 75-59 263rd Street, Glen Oaks, NY 11004, USA Katja Bödeker 3 Department of Psychiatry and Molecular Medicine, Zucker School of [email protected] Medicine at Hofstra/Northwell, Hempstead, NY, USA 124 Page 2 of 31 Curr Psychiatry Rep (2019) 21:124 effective treatment of schizophrenia remains an issue, both due to acceptability of LAIs. Since a comprehensive review of the insufficient treatment of cognition and negative symptoms as literature on the use of LAIs up to 2015 already exists [13], we well as the challenge of treatment nonadherence, which is strong- focused on the time frame 2016–2019. ly linked to recurrent relapses [7, 8]. Given the need for long- term maintenance treatment in schizophrenia [9•], relapse pre- vention is a major goal [10, 11•, 12]. Methods In order to improve adherence to prescribed antipsychotics through less frequent dosing schedules and readily observable We aimed to summarize the recent evidence of RCTs compar- nonadherence, long-acting injectable antipsychotics (LAIs) ing LAIs to placebo, OAPs, or another LAI for schizophrenia- have been developed [13••]. Although in randomized con- spectrum disorders. Therefore, we conducted a systematic lit- trolled trials that systematically include more adherent patients erature search of articles published in PubMed between 01 who know that their medication adherence will be monitored January 2016 and 26 March 2019, using the following search closely [14], LAIs were not superior to oral antipsychotics terms: ((schizophrenia OR schizophreniform OR (OAPs) regarding relapse and treatment continuation [15], schizoaffective OR psychosis OR psychotic) AND (depot and meta-analyses of mirror image and cohort studies that OR long-acting injectable OR injection* OR microsphere* arguably enroll more generalizable patients [14]demonstrated OR decanoate OR palmitate OR enanthate OR monohydrate that LAIs are superior to OAPs in treatment discontinuation OR lauroxil OR nanocrystal)). [16, 17•], relapse [18] and hospitalization [16, 17], time to We included RCTs that investigated LAIs in adults with relapse [18], and hospital days [18]. As schizophrenia is often schizophrenia-spectrum disorders focusing on new LAI for- associated with functional impairments, recent research also mulations (ALNCD and RBP-7000), efficacy of LAIs for focused on the maintenance and improvement of functionality symptom improvement and prevention of relapse and hospi- and quality of life with both oral antipsychotics [19•] and talization, functionality and quality of life, tolerability and LAIs [13]. In terms of tolerability and safety, meta-analyses safety of LAIs, and attitudes toward as well as acceptability have demonstrated that LAIs are comparable to OAPs [20•, of LAIs. Additionally, we considered published expert recom- 21•], with one meta-analysis favoring LAIs over OAPs [18]. mendations for the use of LAIs. We excluded studies in chil- Furthermore, novel long-acting injectable formulations have dren and adolescents, reporting on mixed-age populations emerged, aiming to move from deep intramuscular to subcutane- without reporting results separately for adults, and LAI dose ous injections and/or abolish the need for initial oral cotreatment comparisons. Finally, we also reviewed meta-analytic results or loading injection strategies, which may increase acceptability of RCTs, as long as the meta-analysis was published in [6]. These formulations include RBP-7000 (Perseris™), a long- January 2016 or later. acting injectable formulation of risperidone [22], requiring no Results are summarized first for the individual RCTs focus- oral supplementation and being the first antipsychotic available ing on the following five characteristics/outcomes: [1]FDA as a subcutaneously (intraabdominally) administered LAI [23•], approval trial, [2] efficacy for symptom improvement and and aripiprazole lauroxil nanocrystal dispersion (ALNCD; prevention of relapse/hospitalization, [3] efficacy for Aristada Initio™), a 1-day initiation regimen for the LAI functionality/quality of life, [4] tolerability/safety, and [5]at- aripiprazole lauroxil (AL), reducing oral supplementation to the titudes/acceptability, dividing the results by the comparator first day of administration and enabling faster release of (placebo, OAP, LAI). At the end, results of the meta- aripiprazole into plasma [24]. analyses are summarized for efficacy and safety/tolerability Despite demonstrated advantages of LAIs, they remain large- of LAIs vs. the meta-analyzed comparator. ly underutilized in clinical practice, possibly due to lack of famil- iarity of many physicians, incomplete or inaccurate perceptions about safety and efficacy, medication cost considered in isolation Results without taking into account overall reductions in cost of care due to reduced relapse and hospitalizations, issues with access to Search Results and Study Characteristics treatment, and negative perceptions about injectable therapy among patients, families, and prescribers [13]. The PubMed search resulted in 821 hits. After removal of 776 In this context, this systematic review aimed to summarize articles based on title and abstract review, 45 full text articles evidence from articles published 2016–2019 that reported data were inspected for eligibility. Of these, 14 were excluded for on findings of randomized controlled trials (RCTs) regarding the following reasons: LAI dose comparison (n = 8), short- (i) new long-acting injectable formulations; (ii) the efficacy of acting injectable data (n = 4), no data on LAIs (n = 1), and LAIs for symptom improvement and prevention of relapse duplicate publication (n = 1). Ultimately, we included 31 and hospitalization, functionality, and quality of life; (iii) the RCTs (primary data studies: k = 7; post hoc analyses: k = tolerability and safety of LAIs; and (iv) attitudes toward and 24; individual patients: n = 4738), comparing LAIs vs. Curr Psychiatry Rep (2019) 21:124 Page 3 of 31 124 placebo (studies = 11, n = 1875) and LAIs vs. OAPs (studies = Global Impression Scale-Severity (CGI-S) scores (90 mg: p 7, n = 658) and comparing one LAI vs. another LAI (studies = = 0.0002; 120 mg: p < 0.0001) vs. placebo [28•](Table1). In a 13, n = 2205). Altogether, 20 studies (n = 3812) had a double- post hoc analysis of the same study [28•], the maximum blind (DB) and 11 had a randomized, open-label (ROL) (n = placebo-corrected relative decrease in PANSS score in the 926) design. RBP-7000 group was 5.4%, half of which was achieved at Additionally, five meta-analyses of RCTs of LAIs in plasma concentrations of 4.6 ng/mL
Load more

Recommended publications
  • Ecstasy and the Concomitant Use of Pharmaceuticals
    J.Copeland, P. Dillon & M. Gascoigne Ecstasy and the Concomitant Use of Pharmaceuticals NDARC Technical Report No. 201 ECSTASY AND THE CONCOMITANT USE OF PHARMACEUTICALS Jan Copeland (PhD), Paul Dillon & Michael Gascoigne Technical Report Number 201 ISBN: 1 877027 92 8 ©National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 2004 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 2 ACKNOWLEDGEMENT This study and report was funded by the Australian Government Department of Health and Ageing’s National Illicit Drug Strategy. It was conducted concurrently with a study of aspects of information seeking among ecstasy users and there is some replication of the data presented on demographic characteristics and perception of ecstasy related harms in this Technical Report and Technical Report Number 202. 3 TABLE OF CONTENTS ACKNOWLEDGEMENT 3 TABLE OF CONTENTS 4 TABLE OF TABLES 5 EXECUTIVE SUMMARY 6 INTRODUCTION 7 Anti-depressant medication 8 5-hydroxytryptophan 9 Attention Deficit Hyperactivity Disorder 11 Sildenafil Citrate 12 Benzodiazepines 13 Study Ains 14 METHOD 15 Participants 15 Procedure 15 Measures 15 RESULTS 17 Demographics
    [Show full text]
  • Clopixol Acuphase®)
    Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Version 3.1 – January 2018 GUIDELINE REPLACED Version 3 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED October 2015 NEXT REVIEW DATE January 2021 EXECUTIVE SPONSOR Executive Medical Director ORIGINAL AUTHOR Jed Hewitt – Chief Pharmacist Review / update – 2015 Helen Manuell – Lead Pharmacist (ESx) Review / update - 2018 Jed Hewitt – Chief Pharmacist If you require this document in an alternative format, i.e. easy read, large text, audio or Braille please contact the pharmacy team on 01243 623349. Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Introduction In the past, Acuphase® has often been too widely and possibly inappropriately used, sometimes without full regard being given to the fact that it is a potentially hazardous and toxic preparation with very little published information to support its use. Indeed, the Cochrane Library concludes that there is inadequate data on Acuphase® and no convincing evidence to support its use in acute psychiatric emergency. So far as possible, it should therefore be reserved for the minority of patients who have a prior history of previous use and good response, with use defined in an advance directive. Similarly, as a general rule Acuphase® should not be used for rapid tranquillisation unless such practice is also in accordance with an advance directive. Normally, Acuphase® should never be considered as a first-line drug for rapid tranquillisation as its onset of action will often not be rapid enough in these circumstances. In addition, the administration of an oil-based injection carries very high risk in a highly agitated patient.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
    pharmaceutics Review Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics Francisco José Toja-Camba 1,2,† , Nerea Gesto-Antelo 3,†, Olalla Maroñas 3,†, Eduardo Echarri Arrieta 4, Irene Zarra-Ferro 2,4, Miguel González-Barcia 2,4 , Enrique Bandín-Vilar 2,4 , Victor Mangas Sanjuan 2,5,6 , Fernando Facal 7,8 , Manuel Arrojo Romero 7, Angel Carracedo 3,9,10,* , Cristina Mondelo-García 2,4,* and Anxo Fernández-Ferreiro 2,4,* 1 Pharmacy Department, University Clinical Hospital of Ourense (SERGAS), Ramón Puga 52, 32005 Ourense, Spain; [email protected] 2 Clinical Pharmacology Group, Institute of Health Research (IDIS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain; [email protected] (I.Z.-F.); [email protected] (M.G.-B.); [email protected] (E.B.-V.); [email protected] (V.M.S.) 3 Genomic Medicine Group, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; [email protected] (N.G.-A.); [email protected] (O.M.) 4 Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Citation: Toja-Camba, F.J.; 15706 Santiago de Compostela, Spain; [email protected] Gesto-Antelo, N.; Maroñas, O.; 5 Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Echarri Arrieta, E.; Zarra-Ferro, I.; 46100 Valencia, Spain González-Barcia, M.; Bandín-Vilar, E.; 6 Interuniversity Research Institute for Molecular Recognition and Technological Development,
    [Show full text]
  • Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database
    Antipsychotic Codes Used from Drug Programs Information Network (DPIN) Database Drug Identification Anatomical Therapeutic Chemical Equivalent Generic Product Name Product Description Number (DIN) (ATC) Drug Classification HALOPERIDOL INJECTION 17574 HALDOL INJECTION 5MG/ML N05AD01 HALOPERIDOL TRIFLUOPERAZINE HCL 21865 NOVO-FLURAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21873 NOVO-FLURAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 21881 NOVO-FLURAZINE TAB 10MG N05AB06 TRIFLUOPERAZINE THIORIDAZINE 27375 MELLARIL SUS 10MG/5ML N05AC02 THIORIDAZINE FLUPHENAZINE ENANTHATE 29173 MODITEN ENANTHATE INJ 25MG/ML N05AB02 FLUPHENAZINE THIORIDAZINE HYDROCHLORIDE 37486 NOVO-RIDAZINE 50MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37494 NOVO-RIDAZINE 25MG N05AC02 THIORIDAZINE THIORIDAZINE HYDROCHLORIDE 37508 NOVO-RIDAZINE 10MG N05AC02 THIORIDAZINE CHLORPROMAZINE HCL 232157 NOVO-CHLORPROMAZINE TAB 10MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232807 NOVO-CHLORPROMAZINE TAB 50MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232823 NOVO-CHLORPROMAZINE TAB 25MG N05AA01 CHLORPROMAZINE CHLORPROMAZINE HCL 232831 NOVO-CHLORPROMAZINE TAB 100MG N05AA01 CHLORPROMAZINE LITHIUM CARBONATE 236683 CARBOLITH CAP 300MG N05AN01 LITHIUM TRIFLUOPERAZINE HCL 312746 APO TRIFLUOPERAZINE TAB 5MG N05AB06 TRIFLUOPERAZINE TRIFLUOPERAZINE HCL 312754 APO TRIFLUOPERAZINE TAB 2MG N05AB06 TRIFLUOPERAZINE PIMOZIDE 313815 ORAP TAB 2MG N05AG02 PIMOZIDE PIMOZIDE 313823 ORAP TAB 4MG N05AG02 PIMOZIDE TRIFLUOPERAZINE HCL 326836 APO TRIFLUOPERAZINE TAB 10MG N05AB06
    [Show full text]
  • Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults
    Guidance on the Treatment of Antipsychotic Induced Hyperprolactinaemia in Adults Version 1 GUIDELINE NO RATIFYING COMMITTEE DRUGS AND THERAPEUTICS GROUP DATE RATIFIED April 2014 DATE AVAILABLE ON INTRANET NEXT REVIEW DATE April 2016 POLICY AUTHORS Nana Tomova, Clinical Pharmacist Dr Richard Whale, Consultant Psychiatrist In association with: Dr Gordon Caldwell, Consultant Physician, WSHT . If you require this document in an alternative format, ie easy read, large text, audio, Braille or a community language, please contact the Pharmacy Team on 01243 623349 (Text Relay calls welcome). Contents Section Title Page Number 1. Introduction 2 2. Causes of Hyperprolactinaemia 2 3. Antipsychotics Associated with 3 Hyperprolactinaemia 4. Effects of Hyperprolactinaemia 4 5. Long-term Complications of Hyperprolactinaemia 4 5.1 Sexual Development in Adolescents 4 5.2 Osteoporosis 4 5.3 Breast Cancer 5 6. Monitoring & Baseline Prolactin Levels 5 7. Management of Hyperprolactinaemia 6 8. Pharmacological Treatment of 7 Hyperprolactinaemia 8.1 Aripiprazole 7 8.2 Dopamine Agonists 8 8.3 Oestrogen and Testosterone 9 8.4 Herbal Remedies 9 9. References 10 1 1.0 Introduction Prolactin is a hormone which is secreted from the lactotroph cells in the anterior pituitary gland under the influence of dopamine, which exerts an inhibitory effect on prolactin secretion1. A reduction in dopaminergic input to the lactotroph cells results in a rapid increase in prolactin secretion. Such a reduction in dopamine can occur through the administration of antipsychotics which act on dopamine receptors (specifically D2) in the tuberoinfundibular pathway of the brain2. The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness1.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrCLOPIXOL® Zuclopenthixol Tablets Lundbeck Std. (10 mg and 25 mg zuclopenthixol as zuclopenthixol hydrochloride) Lundbeck standard PrCLOPIXOL-ACUPHASE® 50 mg/mL Zuclopenthixol Intramuscular Injection (45.25 mg/mL zuclopenthixol as zuclopenthixol acetate) Lundbeck standard PrCLOPIXOL® DEPOT 200 mg/mL Zuclopenthixol Intramuscular Injection (144.4 mg/mL zuclopenthixol as zuclopenthixol decanoate) Lundbeck standard Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel October 16th, 2020 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 171198 Page 1 of 34 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................18
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]
  • Psychiatric Medication Information / Arabic 1
    AARRAABBIICC Professor David Castle Ms. Nga Tran St. Vincent’s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric Medication Information / Arabic 2 dosette box blister pack Psychiatric Medication Information / Arabic 3 PRN ANTIPSYCHOTICS ANTIDEPRESSANTS SSRIs (Selective Serotonin Reuptake Inhibitors) SNRIs (Serotonin Noradrenaline Reuptake Inhibitors Psychiatric Medication Information / Arabic 4 Noradrenaline and Specific Serotonin Antagonists (NaSSAs) Noraderenaline Reuptake Inhibitors (NaRIs) NaSSAs NaRIs Tricyclic Antidepressants (TCAs) MOOD STABILISERS Lithium Carbamazepine Sodium Valproate Anxiolytics Benzodiazepines benzhexol benztropine Anticholinergic drugs biperiden Beta Blockers Psychiatric Medication Information / Arabic 5 ® Chlorpromazine (Largactil ), Thioridazine (Aldazine®), Trifluoperazine (Stelazine®), Haloperidol ® ® ® (Serenace , Haldol ), Flupenthixol (Fluanxol ), Zuclopenthixol (Clopixol®) ® ® Risperidone (Risperdal ), Olanzapine (Zyprexa ), Quetiapine (Seroquel®), Clozapine Clozapine ® ® ® (Clopine /Clozaril ), Amisulpride (Solian ), Aripiprazole (Abilify®), Ziprasidone (Zeldox®), Paliperidone (Invega®) ® ® Imipramine (Tofranil ), Amitriptyline (Tryptanol ), Dothiepin (Prothiaden®), Doxepin (Sinequan®), ® ® Nortriptyline (Allegron ), Trimipramine (Surmontil ) (SSRIs) ® ® Fluoxetine (Prozac ), Sertraline (Zoloft ), Citalopram (Cipramil®), Paroxetine (Aropax®), Fluvoxamine ® ® (Luvox ), Escitalopram (Lexapro ) (SNRI)
    [Show full text]
  • Long-Acting Injectable Antipsychotics. Review and Recent Developments
    Review Article Monica Zolezzi, BPharm, MSc. ABSTRACT Long-acting injectable antipsychotics, also known as "depots", were developed in the late 1960s as an attempt to improve compliance and long-term management of schizophrenia. Despite their availability for over 30 years, guidelines for their use and data on patients for whom long-acting injectable antipsychotics are most indicated are sparse and vary considerably. A review of the perceived advantages and disadvantages of using long-acting injectable antipsychotics is provided in this article, as well as a review of the literature to update clinicians on the current advances of this therapeutic option to optimize compliance and long-term management of chronic schizophrenia. Neurosciences 2005; Vol. 10 (2): 126-131 chizophrenia is a chronic disorder for which it is hydrolyze the esterified compound and liberates the Swell recognized that lifelong treatment with parent antipsychotic.2,9,10 Although depot antipsychotics is necessary. Although quite antipsychotics have been available for over 30 successful in treating and preventing relapses,1,2 years, guidelines for their use and data on patients antipsychotics are not readily accepted by patients, for whom long-acting injectables are most indicated thus, non-compliance is common.3,4 Thus, are sparse and vary considerably. In addition, long-acting injectable forms of these medications despite the fact that the use of depot antipsychotics were developed in an attempt to help medication has been extensively promoted to overcome patient compliance
    [Show full text]
  • Should Inverse Agonists Be Defined by Pharmacological Mechanism Or
    CNS Spectrums,(2019), 24 354 – 370. © Cambridge University Press 2018. This is an Open Access article, distributed under the terms , of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. doi:10.1017/S1092852918001098 REVIEW ARTICLE Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics Christoph U. Correll ,1,2 Jennifer Kern Sliwa ,3* Dean M. Najarian ,3 and Stephen R. Saklad4 1 Department of Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, New York 2 Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York 3 Janssen Scientific Affairs LLC, Titusville, New Jersey 4 College of Pharmacy, Pharmacotherapy Division, University of Texas at Austin, San Antonio, Texas With more long-acting injectable (LAI) antipsychotics available for treating schizophrenia, each with variable durations of action (2 weeks to 3 months), it is important to have clear management strategies for patients developing breakthrough psychotic symptoms or experiencing symptomatic worsening on LAIs. However, no treatment guidelines or clinical practice pathways exist; health-care providers must rely on their own clinical judgment to manage these patients. This article provides practical recommendations—based on a framework of clinical, pharmacokinetic, and dosing considerations—to guide clinicians’ decisions regarding management of breakthrough psychotic symptoms.
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]